BELLE‐3 (NCT01633060), which was a randomized, double‐blind, placebo‐controlled, phase III trial, included patients who were HR+/HER2−, AI‐treated, locally advanced BC that had either progressed on treatment or after treatment with everolimus. This evidence concerns the gene HR and breast cancer.